Standard Biotools (LAB) Cash from Financing Activities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cash from Financing Activities data on file, last reported at -$40000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 13.04% year-over-year to -$40000.0 in Q1 2026; TTM through Mar 2026 was $576000.0, a 100.69% increase from a year earlier, with the FY2025 full-year figure at $570000.0, up 100.56% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$40000.0, down from $620000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for LAB reached as high as $213.0 million in Q2 2022 and fell as low as -$54.5 million in Q4 2024.
• Historically, Cash from Financing Activities has averaged $7.2 million across 5 years, with a median of -$112000.0 in 2025.
• Across the five-year window, Cash from Financing Activities soared 18474.29% in 2022 and slumped 23180.0% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$270000.0 in 2022, then plunged by 271.48% to -$1.0 million in 2023, then tumbled by 5335.69% to -$54.5 million in 2024, then jumped by 101.14% to $620000.0 in 2025, then sank by 106.45% to -$40000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$40000.0 in Q1 2026, $620000.0 in Q4 2025, and -$112000.0 in Q3 2025.